<DOC>
	<DOCNO>NCT00866944</DOCNO>
	<brief_summary>The purpose study determine effect adecatumumab alone follow FOLFOX patient R0 resect liver metastasis CRC ( colorectal carcinoma ) compare effect FOLFOX alone .</brief_summary>
	<brief_title>Study Adecatumumab Relative FOLFOX After R0 Resection Colorectal Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histopathologically confirm complete resection ( R0 ) liver metastases colorectal adenocarcinoma Age ≥18 year ECOG performance status ≤ 2 Patient inform , read understood patient information / inform consent form give write informed consent Extrahepatic distant metastasis locally recurrent disease time enrolment Neoadjuvant chemotherapy liver metastases prior surgery Any anticancer chemotherapy within 4 week prior study entry Start Oxaliplatinbased chemotherapy within 9 month prior study entry Any biological anticancer therapy immunotherapy within 4 week prior study entry Any radiotherapy radio frequency ablation ( RFA ) liver prior surgery Treatment investigational product within time range 45 halflives ( t½ ) prior study entry Acute chronic pancreatitis history alcohol induce pancreatitis Liver cirrhosis , acute hepatitis chronic hepatic disease Any unresolved complication prior surgery Persistent neuropathy History malignancy within 5 year prior study start , exception basal cell carcinoma skin , carcinoma situ cervix Ductal Carcinoma Situ ( DCIS ) History inflammatory bowel disease Active severe infection , concurrent disease medical condition deem interfere conduct study judge investigator Use immunesuppressive agent regular use systemic corticosteroid HIV positivity Known hypersensitivity intolerability immunoglobulins general , recombinant human humanize antibody , Folinic Acid , 5Fluorouracil , Oxaliplatin component study drug formulation , know dihydropyrimidine dehydrogenase ( DPD ) deficiency Pregnant nursing woman Women childbearing potential male patient willing use effective form contraception treatment phase study least 6 month thereafter Not willing incapable comply study visit assessment Placed institution due juridical regulatory ruling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Colorectal carcinoma</keyword>
	<keyword>Liver metastasis ( )</keyword>
	<keyword>R0 resection</keyword>
	<keyword>R0 resection liver metastases colorectal cancer</keyword>
</DOC>